Consumer Insights
Uncover trends and behaviors shaping consumer choices today
Procurement Insights
Optimize your sourcing strategy with key market data
Industry Stats
Stay ahead with the latest trends and market analysis.
The Severe Acne VulgarisDrug Pipeline Insight Report by Expert Market Research gives comprehensive insights into severe acne vulgaris drugs currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for severe acne vulgaris. The report includes the analysis of over 100 pipeline drugs and 50+ companies. The severe acne vulgaris pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials including their adverse effects on patients suffering from severe acne vulgaris.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration and ongoing product development activities related to severe acne vulgaris.
Acne vulgaris is a chronic form of acne, characterized by the formation of inflammatory or non-inflammatory skin lesions. It commonly affects the face, but it may spread to the neck, back or chest in some cases. It is commonly triggered by a bacterial species called Cutibacterium acnes and mostly affects young adults. Common symptoms include excessive sebum production, follicular plugging with keratinocytes and colonization by the bacteria. Hormonal imbalance, high sweating, occlusive cosmetics or skin care can be other causes of acne vulgaris.
Treatment for severe acne vulgaris depends on skin type, area and type of lesions as well as grade of acne. Acne is graded in the severe category when the total lesion count is more than 125, the total inflammatory count is greater than 50 and the total comedo is higher than 100. In October 2023, Bausch Health’s Cabtreo (triple combination gel) for treating acne in individuals aged 12 or above. Such drug approvals are expected to stimulate more research, thereby, impacting the drug pipeline for severe acne vulgaris positively.
This section of the report covers the analysis of severe acne vulgaris drugs based on several segmentations including:
By Phase
EMR’s pipeline assessment report covers 50+ drug analyses based on phase.
By Drug Class
EMR’s pipeline assessment report covers 50+ drug analyses based on drug classes:
By Route of Administration
EMR’s pipeline assessment report covers 50+ drug analyses based on the route of administration.
The report covers phase I, phase II, phase III, phase IV, and early phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase II covers a major share of the total clinical trials for severe acne vulgaris. There are around 47 drugs in phase II of severe acne vulgaris drugs.
The drug molecules categories covered under severe acne vulgarispipeline analysis include antibiotics, retinoids, hormonal agents, and anti-inflammatory drugs. Antibiotics like doxycycline, minocycline, and tetracycline may be advised for treating bacterial infections while anti-inflammatory drugs such as corticosteroids can be taken orally or injected into the acne lesion. Drugs are based on the patient’s profile and the severity of the condition.
The EMR report for the severe acne vulgarisdrug pipeline covers the profile of key companies involved in clinical trials and their drugs under development. Below is the list of a few players involved in severe acne vulgaris clinical trials:
PF-05175157
Pfizer's PF-05175157 is in Phase 2 of a 6-week randomized, double-blind, placebo-controlled study. It is under evaluation for its safety and tolerability against treating moderate to severe acne vulgaris in adults.
RA-18C3
RA-18C3 is a human monoclonal antibody, currently in Phase 2 of a 91-day open label trial for treating moderate to severe acne vulgaris in subjects. Sponsored by Janssen Research & Development, LLC, the participants will receive doses on days 0, 21, and 42 (with a total of 3 injections).
FMX101
FMX101 is a topical foam that contains 4% minocycline. Sponsored by Vyne Therapeutics, Inc., it is Phase 3 of a randomized, double-blind, vehicle-controlled study to investigate its safety and efficacy for treating moderate-to-severe acne vulgaris.
Topical SB204
Sponsored by Novan Inc., it is Phase 1 of a single-center, open-label study. The topical is under investigation to treat adolescents with moderate to severe acne vulgaris. The study involves taking blood samples from the participants on Day 1 and Day 21 to characterize systemic exposure to hMAP3 and nitrate.
The Severe Acne Vulgaris Drug Pipeline Insight Report provides a strategic overview of the latest and future landscape of treatments for severe acne vulgaris. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into market trends, regulatory environments, and potential growth opportunities within severe acne vulgaris pipeline insights.
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
Scope of the Report | Details |
Drug Pipeline by Clinical Trial Phase |
|
Route of Administration |
|
Drug Classes |
|
Leading Sponsors Covered |
|
Geographies Covered |
|
Purchase Full Report
Datasheet
Single User License
One User
Five User License
Five Users
Corporate License
Unlimited Users
How To Order
Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-858-608-1494
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City,1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
United States
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
United States (Head Office)
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-858-608-1494
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City, 1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
Share